Ultragenyx stock jumps after FDA approves Fayuvi for Sanfilippo A
FDA approval of Ultragenyx Pharmaceutical’s Fayuvi for children with Sanfilippo syndrome type A sent the shares up about 12% to $14.44 late Thursday.
Shares of Ultragenyx Pharmaceutical climbed after the Food and Drug Administration said it approved the company's Fayuvi for children with Sanfilippo syndrome type A. The stock gained 12%, to $14.44, late Thursday, but has fallen 37% for the year. The agency said this is the first ap…